PFE vs PLTR: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Palantir Technologies Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-16.
Pfizer Inc. ยท Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
VS
Palantir Technologies Inc. ยท Technology
$142.76
-24.3% upside to fair value
Med Conviction Grade C
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric PFE PLTR
Current Price $26.91 $142.76
Fair Value Estimate $35.00 $108.00
Upside to Fair Value +30.1% -24.3%
Market Cap $153.0B $327.1B
Forward P/E 9.5x 209.7x
EV / EBITDA 13.8x โ€”
Price / Sales 2.4x 73.1x
Price / FCF 16.8x 155.7x
Revenue Growth YoY -1.6% +19.1%
Gross Margin 70.3% 82.4%
Operating Margin 24.7% 31.6%
Return on Equity 9.0% 25.7%
Dividend Yield 6.4% โ€”
FCF Yield 5.9% 0.6%
Analyst Consensus Hold Buy
Investment Thesis
PFE โ€” Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seagโ€ฆ
PLTR โ€” Palantir Technologies Inc.
Palantir Technologies develops data analytics and AI software platforms like Gotham and Foundry for government and commercial clients. The business excels with high margins (gross 82.4%, net 36.3%), accelerating growth (Q4 FY2025 revenue up 70% YoY to $1.41B, 2026 guidance $7.19B implying 61% growth), and strong moats in defense and enterprise AI, but trades expensively at 73x P/S versus 5-year mโ€ฆ
Accumulation Zones
Metric PFE PLTR
Zone Low $25.00 $81.00
Zone High $29.00 $92.00
In Buy Zone? Yes No
โ† PFE Research    PLTR Research โ†’    All Research